# Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI

> **NCT00934882** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 45 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Regorafenib (BAY73-4506)

## Key facts

- **NCT ID:** NCT00934882
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2014-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00934882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00934882, "Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00934882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*